ClinicalTrials.gg
Active, not recruitingNCT06723964Updated Dec 9, 2024

A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors

A Phase 1 interventional study of AP505 in Advanced Solid Tumors, sponsored by AP Biosciences Inc.. Active, not recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by AP Biosciences Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Mar 2023, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of AP505 injection in patients with advanced solid tumors. The study will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for AP505.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

AP Biosciences Inc. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to participate in this study, all subjects must meet ALL of the inclusion criteria described.

  1. Voluntarily participate in this study and provide a signed and dated form (ICF).
  2. Male or female aged ≥ 18 years old (inclusive) at the time of signing the ICF.
  3. Patients with and/or cytologically confirmed advanced solid tumor, who have failed established standard medical anti-cancer therapies for a given tumor type or have been intolerant to such therapy, or in the opinion of the Investigator have been considered ineligible for standard therapies on medical grounds, or refused to standard treatment (late or last line). Note: for subjects who are eligible based on intolerance to standard therapy or considered ineligible for standard therapies in the opinion of the investigator, the basis of this determination should be captured in the case report forms.
  4. Willing to comply with the visits, study treatment, laboratory examinations and other study-related procedures and requirements specified in the study protocol.
  5. (ECOG) performance score of 0-1.
  6. Expected survival time of more than 3 months.
  7. Have at least one per version 1.1.
  8. Adequate organ and bone marrow function:

    • Hematology (no blood transfusion, no G-CSF, no medication correction within 2 weeks prior to screening): (ANC) ≥ 1.5×109/L, (PLT) ≥ 100×109/L, (Hb) ≥ 90 g/L.
    • Liver function: total (TBIL) ≤ 1.5× (ULN), (ALT) ≤ 3.0×ULN, aspartate aminotransferase (AST) ≤ 3.0×ULN; for patients with liver : ALT ≤ 5.0×ULN, AST ≤ 5.0×ULN;
    • Renal function: (CrCL) ≥ 50 mL/min (calculated according to Cockcroft-Gault formula);
    • Coagulation function: (PT) ≤ 1.5×ULN or international normalized ratio (INR) ≤ 1.5×ULN, and activated partial thromboplastin time (APTT) ≤ 1.5×ULN.
  9. For female patients:

    • Females of who are not breastfeeding must agree to use highly effective from the time of signing the ICF and use such contraceptives during the study and for at least 6 months after the last dose of the study drug; The blood pregnancy test result (human chorionic gonadotropin, hCG) must be negative within 3 days prior to enrollment.
    • Women who are infertile (i.e., physiologically incapable of becoming pregnant), including those surgically sterilized (having undergone bilateral oophorectomy, bilateral tubal ligation, or hysterectomy), or (non-treatment-induced amenorrhea) for ≥ 12 months prior to screening.
  10. For male patients with fertile female partners, they must agree to use high-efficiency contraception from the time of signing the ICF and to use such contraception during the study and for at least 6 months after the last dose of the study drug.

Exclusion criteria

Exclusion Criteria:

In order to participate in this study, all subjects must meet NONE of the exclusion criteria described.

  1. Have received (ICIs) such as anti-PD-1 monoclonal antibody, anti-PD-L1 monoclonal antibody, anti-CTLA-4 monoclonal antibody, or VEGF inhibitor such as bevacizumab, ramucirumab, apatinib, or regorafenib within 28 days prior to the first dose of the study drug.
  2. Known to the study drug and any of its components; or known history of previous severe allergic reactions to macromolecular protein preparations/monoclonal antibodies or bispecific antibodies.
  3. Female patient who is pregnant or breastfeeding.
  4. Received major surgery within 4 weeks prior to the first dose of the study drug or requiring major elective surgery during the study period.
  5. The adverse reactions caused by previous anti-tumor therapy have not been recovered to ≤ grade 1 per v5.0 (except for alopecia).
  6. Subjects with untreated or symptomatic , spinal cord compression, cancerous meningitis, or other evidence of uncontrolled brain or spinal cord (Exception: Treated and stable symptoms, stable imaging for at least 4 weeks prior to first dose, with no evidence of cerebral edema, and no need for therapy).
  7. Patients with pleural effusion, pericardial effusion or ascites that have shown clinical symptoms or requiring repeated drainage.
  8. Imaging during the screening period showed that the tumor surrounded important blood vessels or the presence of obvious tumor necrosis and cavitation, and the Investigator judged that entering the study may cause bleeding risk.
  9. Known history of (HIV) infection (positive for HIV 1/2 antibody test) or diseases related to acquired immunodeficiency syndrome (AIDS).
  10. Patients with infection undergoing treatment or requiring treatment (defined as hepatitis B surface antigen (HBsAg) positive, and HBV DNA >1000 copies/mL (200IU/mL) or above the lower limit of the detection, whichever is higher); or patients with antibody (HCV-Ab) positive and HCVRNA quantification > the of the testing unit; or patients with known active syphilis infection.
  11. Patients with uncontrolled bacterial, viral, fungal infections, or other pathogen infections (such as mycoplasma, parasites, etc.) that need systemic treatment within 4 weeks prior to the first dose of the study drug.
  12. Known history of serious cardiovascular disease, including but not limited to:

    • Ventricular arrhythmia requiring clinical intervention.
    • Acute coronary syndrome (myocardial infarction and angina pectoris) within 6 months prior to the first dose of the study drug.
    • Congestive heart failure ( (NYHA) class ≥ II) or (LVEF) \< 50%;
    • > 470 msec
    • Uncontrolled hypertension (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90 mmHg) after standard of care or poor compliance to antihypertensive therapy.
    • Major vascular disease (e.g., aortic aneurysm requiring surgery).
  13. Patients with coagulation disorders, bleeding disorders, or other conditions having bleeding risk as judged by the Investigator, such as: skin wounds, surgical sites, trauma sites, mucosal severe ulcers or fractures that are not completely healed, or active gastroduodenal ulcer, intestinal obstruction, ulcerative colitis, esophagogastric varices, gastrointestinal perforation, etc. within 6 months before the first dose of the study drug.
  14. Patients with ≥ grade 2 pulmonary hemorrhage/hemoptysis (according to NCI-CTCAE v5.0) within 1 month before the first dose of the study drug.
  15. Patients with or other minor surgery within 7 days before the first dose of the study drug, except for placement of vascular access devices.
  16. Patients experiencing arterial or venous thrombosis, stroke, or within 6 months before the first dose of the study drug.
  17. Have received unstable doses of anticoagulant or thrombolytic drugs within 14 days of the first dose of the study drug. Please note that prophylactic use of low molecular weight heparin is allowed in the study.
  18. Have received chronic treatment with aspirin (> 325 mg/day) or non-steroidal anti-inflammatory drugs known to inhibit function; or received dipyridamole, ticlopidine, clopidogrel, or cilostazol within 14 days of first dose of the study drug.
  19. Patients with diabetes mellitus poorly controlled by standard therapy ( HbA1c >8%).
  20. Patients with current or past idiopathic pulmonary fibrosis or idiopathic pneumonia; current acute lung disease, interstitial lung disease or pneumonia (except for local interstitial pneumonia induced by radiotherapy), pulmonary fibrosis, etc.; Severe breathing difficulties, pulmonary insufficiency, or continuous oxygen inhalation.
  21. Patients with active disease, or history of autoimmune disease requiring systemic treatment within 2 years prior to screening, including but not limited to: myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. Patients with the following conditions are eligible: hypothyroidism that can be controlled by hormone replacement therapy only, skin diseases (eg, vitiligo, psoriasis) that do not require systemic treatment, controlled celiac disease.
  22. Received systemic corticosteroid treatment (prednisone > 10 mg/day or equivalent dose of similar drugs) or other systemic treatment within 14 days before the first dose of the study drug.

    Patients with the following conditions are permitted: Treatment with topical, ocular, intra-articular, intranasal, or inhaled corticosteroids with minimal systemic absorption; OR prophylactic short-term (≤ 7 days) use of corticosteroids (eg, hypersensitivity to contrast agent)); OR for the treatment of nonautoimmune diseases (such as delayed hypersensitivity reactions caused by contact allergens).

  23. Received systemic antitumor therapy (chemotherapy, targeted therapy, biologic therapy, etc.) within 4 weeks or 5 half-lives (whichever is longer) before the first dose of study treatment; Received small molecule tyrosine kinase inhibitor therapy or hormonal antitumor therapy within 2 weeks before the first dose; received non-specific immunomodulatory therapy within 2 weeks before the first dose (such as interleukin, interferon, thymosin, cyclophosphamide, methotrexate, thalidomide, tumor necrosis factor, etc., excluding IL-11 for the treatment of thrombocytopenia); received Chinese herbal medicines or Chinese patent medicines with anti-tumor indications within 1 week before the first dose of the study drug.
  24. For patients with hepatocellular carcinoma: Received locoregional treatment of the liver (such as transarterial chemoembolization, transcatheter embolization, hepatic arterial infusion, radiotherapy, radioembolization, or ablation) within 4 weeks prior to the first dose of the study drug.
  25. Previously received organ or hematopoietic stem cell transplantation requiring the use of immunosuppressive agents.
  26. History of other tumors within 5 years before screening, excluding skin basal cell carcinoma, skin squamous cell carcinoma, and cervical carcinoma in situ who underwent successful radical resection.
  27. Received an attenuated vaccine within 4 weeks before screening or planned to receive an attenuated vaccine during the study.
  28. Patients who participated in other clinical study and received other agents or treatment within 4 weeks or 5 half-lives (whichever is longer) before the first dose of the study drug.
  29. History of alcohol or drug abuse within 12 months prior to the first dose (for patients diagnosed with drug or alcohol abuse prior to 12 months prior to first dose, Enrollment only if no evidence of actual drug or alcohol abuse within 12 months prior to first dose).
  30. Patient with any other medical or psychological condition, that is deemed by the Investigator to be likely to interfere with his/her ability to sign the , cooperate, or participate in the study.
  31. Patients with other serious systemic diseases or conditions who are deemed unsuitable to participate in this clinical study at the judgement of the Investigator.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    AP505 0.035 mg/kg

    AP505 0.035 mg/kg Open Label

    Drug: AP505

  • Experimental
    AP505 0.12 mg/kg

    AP505 0.12 mg/kg Open Label

    Drug: AP505

  • Experimental
    AP505 0.4 mg/kg

    AP505 0.4 mg/kg Open Label

    Drug: AP505

  • Experimental
    AP505 1.2 mg/kg

    AP505 1.2 mg/kg Open Label

    Drug: AP505

  • Experimental
    AP505 4.0 mg/kg

    AP505 4.0 mg/kg Open Label

    Drug: AP505

  • Experimental
    AP505 8.0 mg/kg

    AP505 8.0 mg/kg Open Label

    Drug: AP505

  • Experimental
    AP505 11.0 mg/kg

    AP505 11.0 mg/kg Open Label

    Drug: AP505

  • Experimental
    AP505 15.0 mg/kg

    AP505 15.0 mg/kg Open Label

    Drug: AP505

  • Experimental
    AP505 20.0 mg/kg

    AP505 20.0 mg/kg Open Label

    Drug: AP505

  • Experimental
    AP505 25.0 mg/kg

    AP505 25.0 mg/kg Open Label

    Drug: AP505

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-Escalation : DLT Assessment

    Number of Participants With Dose Limiting Toxicity (DLT)

    Time frame: From Day1 to Day15 after first dose of AP505

  2. AE Assessment

    All AEs and SAEs will be collected, regardless of the relationship to the IP.

    Time frame: From screening to follow-up period which includes safety follow-up (30/60/90 days after last dose) and survival follow-up (every 3 months until subject loss to follow-up, death, withdrawal of consent, or study termination, whichever occurs first).

  3. Determine the maximum tolerated dose (MTD)

    Time frame: From first dose of AP505 until 28 days after the last dose of AP505

  4. Determine the recommended phase II dose (RP2D)

    Time frame: From first dose of AP505 until 28 days after the last dose of AP505

Secondary outcomes

  1. To evaluate the pharmacokinetic (PK) profile of AP505 in patients with advanced solid tumors

    Peak Plasma Concentration (Cmax) Analysis

    Time frame: From C1D1 until 7 days after treatment discontinuation/ termination.

  2. To evaluate the pharmacokinetic (PK) profile of AP505 in patients with advanced solid tumors

    Area under the plasma concentration versus time curve (AUC) Analysis

    Time frame: From first dose until 7 days after treatment discontinuation/ termination.

  3. To evaluate the pharmacokinetic (PK) profile of AP505 in patients with advanced solid tumors

    Terminal elimination half-life (t1/2) Analysis

    Time frame: From first dose until 7 days after treatment discontinuation/ termination.

  4. To evaluate the pharmacokinetic (PK) profile of AP505 in patients with advanced solid tumors

    Time to reach the maximum observed concentration (Tmax) Analysis

    Time frame: From first dose until 7 days after treatment discontinuation/ termination

  5. To characterize the immunogenicity profile of AP505 in patients with advanced solid tumors

    Immunogenicity indicators: the level of anti-drug antibody (ADA).

    Time frame: From C1D1 (Cycle 1 is 15 days ; Cycle 2 onwards: each cycle is 28 days), until safety follow up (up to 90 days after the last dose).

  6. To characterize the immunogenicity profile of AP505 in patients with advanced solid tumors

    Immunogenicity indicators: the level of NAb (if ADA is positive).

    Time frame: From C1D1 (Cycle 1 is 15 days ; Cycle 2 onwards: each cycle is 28 days), until safety follow up (up to 90 days after the last dose).

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Oct 2024, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2024
First posted
Dec 9, 2024
StartActual
Mar 30, 2023
Primary completionActual
Oct 31, 2024
CompletionEst.
Nov 30, 2025
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06723964
Lead sponsor
AP Biosciences Inc.
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Mar 30, 2023
Primary completion
Oct 31, 2024
Completion
Nov 30, 2025 (estimated)
Last update
Dec 9, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-L1/Anti-VEGF Bispecific Antibody AP505

Start the discussion